Liquidity	3 Months Ended
Mar. 31, 2017
Liquidity [Abstract]
Liquidity	2. Liquidity The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances could raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. As of March 31, 2017, the Company had cash and cash equivalents of $2.2 million. On May 10, 2017, the Company completed an underwritten public offering of common stock, pre-funded warrants and common warrants, resulting in net proceeds to the Company of approximately $9.1 million (see Note 12). In addition, the Company has filed an Australian tax return for the year 2016 and currently expects receipt of approximately $1.8 million in tax rebate incentive payments from the Australian tax authority in the third quarter of 2017, subject to review of the tax return by Australian tax authorities. There can be no assurance that the Company will receive such tax rebate when or in the amount currently anticipated, or at all. Management has made operational changes that are expected to reduce cash expenditures in 2017 and support the Company’s strategic emphasis on precisely targeted personalized bacteriophage therapies. Considering the Company’s current cash resources, including the net proceeds received from the public offering in May 2017, management believes the Company’s existing resources will be sufficient to fund the Company’s planned operations until the end of the second quarter of 2018. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital.

2. Liquidity

The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances could raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.

As of March 31, 2017, the Company had cash and cash equivalents of $2.2 million. On May 10, 2017, the Company completed an underwritten public offering of common stock, pre-funded warrants and common warrants, resulting in net proceeds to the Company of approximately $9.1 million (see Note 12). In addition, the Company has filed an Australian tax return for the year 2016 and currently expects receipt of approximately $1.8 million in tax rebate incentive payments from the Australian tax authority in the third quarter of 2017, subject to review of the tax return by Australian tax authorities. There can be no assurance that the Company will receive such tax rebate when or in the amount currently anticipated, or at all.

Management has made operational changes that are expected to reduce cash expenditures in 2017 and support the Company’s strategic emphasis on precisely targeted personalized bacteriophage therapies. Considering the Company’s current cash resources, including the net proceeds received from the public offering in May 2017, management believes the Company’s existing resources will be sufficient to fund the Company’s planned operations until the end of the second quarter of 2018. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital.